Pliva Holders Vote for Barr Deal

Reports say the U.S. company has enough shares to complete the acquisition.
Publish date:

Barr Laboratories


appears to have secured enough shares to acquire the Croatian generic-drug company



According to reports by




that cited information from Croatian regulators, Barr has received nearly 73% of Pliva's shares in a tender offer.

Barr needed a majority of Pliva's shares to complete the $2.5 billion offer as it bid against Iceland's

Actavis Group


The tender offer is scheduled to expire at midnight Wednesday, and the official results will take about a week to count. The combination of Barr and Pliva will create the world's third-largest generic-drug company, behind

Teva Pharmaceutical Industries

(TEVA) - Get Report

and the Sandoz unit of


(NVS) - Get Report